Shareholders are very likely to turn down the Michael Saylor pitch, Polymarket bettors are predicting. …
BusinessGlobeNewswire
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
– Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 …